Astri Therapeutics Inc (ATXS)

$ATXS added 2040 shares..good luck

@TALENT_ON_LOAN_FROM_GOD Hi what are your thoughts on $ATXS ? Got good news but didn't jump

$ATXS If CLDX jumps on HAE data and this one stays flat, you know manipulation is real

$ATXS they played the same games initially with $SGMT after the phase 3 results. We see how that played out a few days later. Large orders have been pouring in for a week straight in this. Its time is coming

HC Wainwright & Co. has updated their rating for Astria Therapeutics ( $ATXS ) to Buy with a price target of 16.

$ATXS congrats to those who bought the dip. My guess is theyll run this hard monday. Positive phase 2 results with phase 3 roll out already underway. It being still at these levels is a joke

$ATXS Astria Therapeutics Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual Congress. pt $10

$ATXS can she push higher?👀...👀

$ATXS (+14.3% pre) Astria Therapeutics Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual Congress https://ooc.bz/l/67951

$ATXS Look at those Q3M data! Yummy!

$ATXS Astria announces initial results from ALPHA-SOLAR target enrollment group Astria Therapeutics announced initial results from the target enrollment group in the ongoing ALPHA-SOLAR long-term open-label trial evaluating navenibart, a monoclonal antibody inhibitor of plasma kallikrein, in hereditary angioedema patients. These results demonstrated robust overall reduction in the monthly attack rate. These results further support navenibart's favorable safety and tolerability profile, and potential every three- and every six-month dosing regimens. Navenibart demonstrated overall attack-freedom of 50% over six months, which is the longest period of follow-up for all 16 patients to date. All patients remain in the ALPHA-SOLAR trial. Navenibart was well-tolerated with no severe or serious treatment-emergent adverse events and no discontinuations. One participant experienced two treatment-related, mild injection site reactions that resolved without treatment. There were no injection site reactions of pain. The safety profile of navenibart in patients with HAE was favorable through more than 17 months of cumulative follow-up since the initiation of navenibart in ALPHA-STAR. The results shared above are available in a poster presented at the European Academy of Allergy and Clinical Immunology annual congress on June 13.

$ATXS Astria Therapeutics Reports Initial Results From Target Enrollment Group In Ongoing ALPHA-SOLAR Long-Term Open-Label Trial Evaluating Navenibart In HAE Patients

$PCSA phase 2 data due "mid summer 2025". Chart breakout. And warrants at higher prices $ATXS phase 1b/2 data presentation coming friday. Chart screams breakout. And whales have been loading $HSDT bought back in a entry for a bounce tomorrow. CTB ridiculously high. High volume off positive news today. Rsi is cold despite running 100%+ today just to drop on fud. Offering still not publically closed. $SGMT still holding because the recent PR and pipeline is just too hot to not see continuation Follow for more BANGERS! Weve been on a heat check recently! 🚀🤑

$ATXS 🤫 phase 1b/2 data reveal Friday

$HSDT 🔥 runners into close $PCSA getting hot as we await phase 2 news $ATXS next as its being loaded by big money as phase 1b/2 data comes out Friday

$ATXS Come on now..... SB $10!

$ATXS Pile it high and deep

$ATXS News out $ATXS Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Annual Congresshttps://marketwirenews.com/news-releases/astria-therapeutics-to-present-at-upcoming-european--4722217143984413.html

$ATXS Been holding this for a long time and it's finally moving back up. Looking like we may see double digits soon.

$ATXS winner.... $TIL winner.....

$ATXS Oh yeah.... Go Jill!

$ATXS STRONG